Baseline characteristics of patients included in the analysis.

<p>cART: combination Antiretroviral Therapy.</p><p><b>ANRS CO3 Aquitaine Cohort, 2000–2007.</b></p

Factors associated with the hazard of bacterial pneumonia among HIV-infected patients in the era of cART.

<p>*Time-updated variables.</p><p>cART: combination Antiretroviral Therapy.</p><p>CI: Confidence Interval.</p><p><b>ANRS CO3 Aquitaine Cohort, 2000–2007.</b></p

Association between baseline 25OH Vitamin D level and antibody response to hepatitis B vaccination in the ANRS HB03 VIHVAC B trial (proportional logistic regression model, multivariable analysis, n = 333 with non missing covariates).

<p>Association between baseline 25OH Vitamin D level and antibody response to hepatitis B vaccination in the ANRS HB03 VIHVAC B trial (proportional logistic regression model, multivariable analysis, n = 333 with non missing covariates).</p

Association between baseline 25OH Vitamin D status and response to hepatitis B vaccination in the ANRS HB03 VIHVAC B trial (n = 339).

<p>Association between baseline 25OH Vitamin D status and response to hepatitis B vaccination in the ANRS HB03 VIHVAC B trial (n = 339).</p

Baseline characteristics of the study populations in the ANRS HB03 VIHVAC B trial and the ANRS 114-PNEUMOVAC sub-study.

<p>Baseline characteristics of the study populations in the ANRS HB03 VIHVAC B trial and the ANRS 114-PNEUMOVAC sub-study.</p

Correlations between baseline 25OHD level and change in cellular immune responses between W0 and W4 in the group having received the 7-valent conjugate vaccine prime containing the diphtheria-derived carrier protein CRM₁₉₇ at W0, ANRS-114 PNEUMOVAC sub-study (n = 11).

<p>Correlations between baseline 25OHD level and change in cellular immune responses between W0 and W4 in the group having received the 7-valent conjugate vaccine prime containing the diphtheria-derived carrier protein CRM₁₉₇ at W0, ANRS-114 PNEUMOVAC sub-study (n = 11).</p

Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort

<div><p>Objective</p><p>To describe trends and determinants of severe morbidity in HIV-infected women and men.</p><p>Design</p><p>A French prospective cohort of HIV-infected patients of both sexes and all transmission categories.</p><p>Methods</p><p>We used hospital admission data from January 2000 to December 2008. A severe morbid event (SME) was defined as a clinical event requiring hospitalization for ≥48 h, several events could be reported during hospitalization. Yearly incidence rates of SME were estimated and compared using Generalized Estimating Equations.</p><p>Results</p><p>Among 4,987 patients (27% women), followed for a median of 8.7 years, 1,473 (30%) were hospitalized (3,049 hospitalizations for 5,963 SME). The yearly incidence rate of hospitalization decreased in men, from 155 in 2000 to 80/1,000 person-years (PY) in 2008 and in women, from 125 to 71/1,000 PY, (p<0.001). This trend was observed for all SME except for hepatic events, stable in men (15 to 13/1,000 PY) and increasing in women (2.5 to 11.5), cardiovascular events increasing in men (6 to 10/1,000 PY) and in women (6 to 14) and non-AIDS non-hepatic malignancies increasing in men (4 to 7/1,000 PY) and stable in women (2.5). Intraveneous drug users, age >50 years, HIV RNA >10,000 copies, CD4 <500/mm³, AIDS stage, hepatitis C co-infection and cardiovascular risk factors (diabetes, high blood pressure, and tobacco use) were associated with SME.</p><p>Conclusions</p><p>HIV-infected individuals in care in France require less and less frequently hospitalization. Women are now presenting with severe hepatic and cardio-vascular events. Disparities in SME between men and women are primarily explained by different exposure patterns to risk factors. Women should be targeted to benefit cardiovascular prevention policies as well as men.</p></div

Incidence rates of severe morbid events according to sex (ANRS CO3 Aquitaine Cohort 2000–2008).

<p>p₁ : Poisson regression test for trend, p₂ : Year*sex interaction test. Fig. 3a. AIDS events, p₁<0.001, p₂<0.001. Fig. 3b. Bacterial infections, p₁<0.01, p₂ = 0.99. Fig. 3c. Psychiatric events, p₁ = 0.25, p₂<0.005. Fig. 3d. Hepatic events, p₁ = 0.18, p₂ = 0.48. Fig. 3e. Cardiovascular events, p₁ = 0.25, p₂ = 0.83. Fig. 3f. Non-AIDS, non-hepatic malignancies, p₁ =  0.18, p₂<0.002.</p

Distribution of risk factors at the end of follow-up among 209 patients with incident CKD and 4141 without CKD stratified by exposure to tenofovir, ANRS CO3 Aquitaine Cohort 2004–2012.

<p>Data are n (%).</p

Evolution of yearly incidence rates of hospitalization according to sex (ANRS CO3 Aquitaine Cohort 2000–2008).

<p>Evolution of yearly incidence rates of hospitalization according to sex (ANRS CO3 Aquitaine Cohort 2000–2008).</p